Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 3/2014

01-06-2014

Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies

Authors: Jennifer C. Stone, Justin Clark, Ross Cuneo, Anthony W. Russell, Suhail A. R. Doi

Published in: Pituitary | Issue 3/2014

Login to get access

Abstract

Estrogen and selective estrogen receptor modulator (SERM) treatments for acromegaly have received limited attention since the development of newer pharmacologic therapies. There has been ongoing research evidence suggesting their utility in the biochemical control of acromegaly. Therefore, the aim of this meta-analysis was to synthesise current evidence with a view to determining to what extent and in which acromegalic patient subsets do estrogen and SERMs reduce IGF-1 levels. A literature search was conducted (finished December 2012), which included all studies pertaining to estrogen or SERM treatment and IGF-1. Seven patient subsets were identified from six published observational studies, and were pooled using meta-analytic methods. Overall, the pooled mean loss in IGF-1 was −29.09 nmol/L (95 % CI −37.23 to −20.95). A sensitivity analysis indicated that women receiving estrogen had a substantially greater reduction in IGF-1 levels compared with women receiving SERMs, with a weighted mean loss in IGF-1 of −38.12 nmol/L (95 % CI −46.78 to −29.45) compared with −22.91 nmol/L (95 % CI −32.73 to −13.09). There was a trend that did not reach statistical significance for men receiving SERM treatment at −11.41 nmol/L (95 % CI −30.14 to 7.31). It was concluded that estrogen and SERMs are a low cost and effective treatment to achieve control of IGF-1 levels in acromegalic women either as concomitant treatment for refractory disease, or where access to conventional therapy is restricted. Their use in men requires further study.
Appendix
Available only for authorised users
Literature
1.
Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK (2011) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract 17(Suppl 4):1–44CrossRefPubMed
2.
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol metab 93(1):61–67CrossRefPubMed
3.
Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446CrossRefPubMed
4.
Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153(6):737–740CrossRefPubMed
5.
Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89–95CrossRefPubMed
6.
Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J clin endocrinol metab 83(10):3419–3426PubMed
7.
Anagnostis P, Efstathiadou ZA, Polyzos SA, Adamidou F, Slavakis A, Sapranidis M, Litsas ID, Katergari S, Selalmatzidou D, Kita M (2011) Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract 65(8):896–902CrossRefPubMed
8.
Fukuda I, Hizuka N, Murakami Y, Itoh E, Yasumoto K, Sata A, Takano K (2001) Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women’s Medical University. Intern Med 40(10):987–992CrossRefPubMed
9.
Minniti G, Jaffrain-Rea ML, Esposito V, Santoro A, Tamburrano G, Cantore G (2003) Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature. Endocr Relat Cancer 10(4):611–619CrossRefPubMed
10.
Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152(3):379–387CrossRefPubMed
11.
Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72(2):203–208CrossRef
12.
Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 147(3):243–251 discussion 250–241CrossRef
13.
Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Acromegaly Consensus, G.: guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509–1517CrossRefPubMed
14.
Melmed S (1993) Medical management of acromegaly–what and when? Acta Endocrinol (Copenh) 129(Suppl 1):13–17
15.
Lacy CF, Armstrong LL, Goldman MP, Lance LL (2013) Drug information handbook, 22nd edn. Lexi-Comp, Inc., Hudson
16.
Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens J-L, Mahler C, Beckers A (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 83(2):374–378CrossRefPubMed
17.
Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82(2):518–523CrossRefPubMed
18.
Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G, Gelli D (1998) Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 139(5):516–521CrossRefPubMed
19.
Jackson SNJ, Fowler J, Howlett TA (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol 46(6):745–749CrossRef
20.
Mercado M, Borges F, Bouterfa H, Chang T.-C, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, on behalf of the, S. M. S. B. S. G. (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 66(6):859–868
21.
Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W (2002) Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87(1):99–104CrossRefPubMed
22.
Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82(1):18–22PubMed
23.
Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P (2007) Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol 67(2):282–289CrossRef
24.
Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jiménez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM (2000) Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol 53(5):577–586CrossRef
25.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. The Lancet 358(9295):1754–1759CrossRef
26.
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Haggstrom M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1,288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589–1597CrossRefPubMed
27.
Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord 9:20PubMedCentralCrossRefPubMed
28.
Cozzi R, Attanasio R, Oppizzi G, Orlandi P, Giustina A, Lodrini S, Da Re N, Dallabonzana D (1997) Effects of tamoxifen on GH and IGF-I levels in acromegaly. J Endocrinol Invest 20(8):445–451CrossRefPubMed
29.
Cozzi R, Barausse M, Lodrini S, Lasio G, Attanasio R (2003) Estroprogestinic pill normalizes IGF-I levels in acromegalic women. J Endocrinol Invest 26(4):347–352CrossRefPubMed
30.
Attanasio R, Barausse M, Cozzi R (2003) Raloxifene lowers IGF-I levels in acromegalic women. Eur J Endocrinol 148(4):443–448CrossRefPubMed
31.
Dimaraki E, Symons K, Barkan A (2004) Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 150(4):481–487CrossRefPubMed
32.
33.
Vallette S, Serri O (2010) Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly? Pituitary 13(4):311–314CrossRefPubMed
34.
Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ (1980) Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med 69(4):571–575CrossRefPubMed
35.
Duschek EJ, Gooren LJ, Netelenbos C (2005) Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas 51(3):286–293CrossRefPubMed
36.
Birzniece V, Sutanto S, Ho KK (2012) Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators. J Clin Endocrinol Metab 97(4):E521–E527CrossRefPubMed
37.
Duschek EJ, Valk-de Roo GW, Gooren LJ, Netelenbos C (2004) Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. Fertil Steril 82(2):384–390CrossRefPubMed
38.
Weissberger AJ, Ho KK, Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72(2):374–381CrossRefPubMed
39.
Helle SI, Holly JM, Tally M, Hall K, Vander Stappen J, Lonning PE (1996) Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 69(4):335–339CrossRefPubMed
40.
da Silva BB, Moita DS, Pires CG, Sousa-Junior EC, dos Santos AR, Lopes-Costa PV (2007) Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene. Int Semin Surg Oncol 4:18PubMedCentralCrossRefPubMed
41.
Cakmak A, Posaci C, Dogan E, Caliskan S, Guclu S, Altunyurt S (2005) Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. Am J Obstet Gynecol 193(2):347–351CrossRefPubMed
42.
Balogh A, Kauf E, Vollanth R, Graser G, Klinger G, Oettel M (2000) Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH). Contraception 62(5):259–269CrossRefPubMed
43.
Gibney J, Johannsson G, Leung KC, Ho KK (2005) Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J Clin Endocrinol Metab 90(7):3897–3903CrossRefPubMed
44.
Stamatakis E, Weiler R, Ioannidis JP (2013) Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest 43(5):469–475CrossRefPubMed
45.
Waffenschmidt S, Janzen T, Hausner E, Kaiser T (2013) Simple search techniques in PubMed are potentially suitable for evaluating the completeness of systematic reviews. J Clin Epidemiol 66(6):660–665CrossRefPubMed
46.
47.
Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57(4):555–559CrossRefPubMed
48.
Doi SA, Barendregt JJ, Mozurkewich EL (2011) Meta-analysis of heterogeneous clinical trials: an empirical example. Contemp Clin Trials 32(2):288–298CrossRefPubMed
49.
Higgins JP, Deeks JJ (2008) Chapter 7: Selecting studies and collecting data. In: Higgins J, Green S (eds.) Cochrane Handbook for Systematic Reviews of Interventions V5.0.1 [updated Sept 2008]. The Cochrane Collaboration
50.
Takkouche B, Cadarso-Suarez C, Spiegelman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 150(2):206–215CrossRefPubMed
51.
Onitilo AA, Doi SAR, Barendregt JJ (2013) Chapter 15: meta-analysis II Interpretation and use of outputs. In: Doi SA, Williams GM (eds) Methods Clin Epidemiol. Springer-Verlag, Berlin, pp 253–266CrossRef
52.
Suikkari AM, Tiitinen A, Stenman UH, Seppala M, Laatikainen T (1991) Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease. Fertil Steril 55(5):895–899PubMed
53.
Duursma SA, Bijlsma JW, Van Paassen HC, van Buul-Offers SC, Skottner-Lundin A (1984) Changes in serum somatomedin and growth hormone concentrations after 3 weeks oestrogen substitution in post-menopausal women; a pilot study. Acta Endocrinol (Copenh) 106(4):527–531
54.
Dawson-Hughes B, Stern D, Goldman J, Reichlin S (1986) Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement. J Clin Endocrinol Metab 63(2):424–432CrossRefPubMed
55.
Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR (1996) Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 81(8):2848–2853PubMed
56.
Leung KC, Johannsson G, Leong GM, Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25(5):693–721CrossRefPubMed
57.
Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ, Ho KK (2003) Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci USA 100(3):1016–1021PubMedCentralCrossRefPubMed
58.
Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO (1996) Both oral and transdermal estrogen increase growth hormone release in postmenopausal women–a clinical research center study. J Clin Endocrinol Metab 81(6):2250–2256PubMed
59.
Helle SI, Omsjo IH, Hughes SC, Botta L, Huls G, Holly JM, Lonning PE (1996) Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf) 45(6):727–732CrossRef
60.
Birzniece V, Ho KK (2012) Growth and development: patching up a better pill for GH-deficient women. Nat Rev. Endocrinol 8(4):197–198CrossRefPubMed
61.
Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med 348(7):618–629CrossRefPubMed
62.
Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK (2005) Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289(2):E266–E271CrossRefPubMed
63.
Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK (2003) Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin Endocrinol (Oxf) 59(6):690–698CrossRef
64.
Heald A, Selby PL, White A, Gibson JM (2000) Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. Am J Obstet Gynecol 183(3):593–600CrossRefPubMed
65.
Campagnoli C, Biglia N, Lanza MG, Lesca L, Peris C, Sismondi P (1994) Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Prelim Rep. Maturitas 19(1):25–31CrossRef
66.
Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German pegvisomant observational study. Eur J Endocrinol 156(1):75–82CrossRefPubMed
67.
Grynberg M, Salenave S, Young J, Chanson P (2010) Female gonadal function before and after treatment of acromegaly. J Clin Endocrinol Metabol 95(10):4518–4525CrossRef
68.
Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA (1997) Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 46(1):69–74CrossRef
69.
70.
Bijlsma JW, Duursma SA (1986) Serum concentrations of somatomedins and growth hormone in relation to bone metabolism in acromegaly and thyroid dysfunction. Clin Exp Rheumatol 4(2):105–110PubMed
71.
Deller JJ Jr, Di Raimondo VC, Grodsky GM, Forsham PH (1966) Acromegaly. The effects of various steroid hormones on the insulin-induced growth hormone response. Calif Med 104(1):1–5PubMedCentralPubMed
72.
Ho KK, Valiontis E, Waters MJ, Rajkovic IA (1993) Regulation of growth hormone binding protein in man: comparison of gel chromatography and immunoprecipitation methods. J Clin Endocrinol Metab 76(2):302–308PubMed
Metadata
Title
Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies
Authors
Jennifer C. Stone
Justin Clark
Ross Cuneo
Anthony W. Russell
Suhail A. R. Doi
Publication date
01-06-2014
Publisher
Springer US
Published in
Pituitary / Issue 3/2014
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-013-0504-2

Other articles of this Issue 3/2014

Pituitary 3/2014 Go to the issue

OriginalPaper

Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review

OriginalPaper

Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in vitro

OriginalPaper

Hypothalamitis: a diagnostic and therapeutic challenge

OriginalPaper

MTHFR C677T polymorphism, folate status and colon cancer risk in acromegalic patients

OriginalPaper

Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study

OriginalPaper

Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits